Business concern about Lilly over outcome of Zyprexa litigation

from Reuters:

The biggest potential source of spread widening is an upcoming court decision that will determine whether Eli Lilly can keep the patent for its blockbuster schizophrenia drug, Zyprexa. The drug generates about a third of the company's sales.